In the last decade, nanobiotechnology research has emerged as a revolutionising new approach to the 21 st century pharmaceutical challenges, offering valuable gains in a vast set of biomedical applications. In the field of bone tissue engineering, a broad range of nanotechnology-based delivery systems have been researched and the most recent developments in high-throughput technology and in silico approaches are creating very high expectations.
Introduction
A full list of abbreviations used is given in Table 1 . Presently, medics dealing with skeletal diseases have a wide variety of therapeutic agents at their disposal. Factors such as, antibiotics, anticancer, anti-inflammatory, growth factors, enzymes, antibodies, bioactive proteins, cells and non-viral genes (DNAs and RNAs) are currently being addressed for the treatment of bone diseases (Bose and Tarafder, 2012) . Still, most of the currently available clinical therapies have significant drawbacks associated and there is no effective treatment for some of the most common bone disorders such as osteoporosis, osteoarthritis, osteomyelitis, infections, bone cancer and fracture repair . In most cases, the balance between medication side-effects and treatment efficacy remains a major issue and there is a high demand for delivery vehicles that can provide adequate, sustained and localised presentation of drugs in a time-dependent manner.
The majority of the current drugs are administered orally or parenterally but when administered alone, drugs are usually rapidly cleared from circulation showing very low bioavailability and strong limitations in the efficient delivery to the required site of injury (Gittens et al., 2005; Hirabayashi and Fujisaki, 2003; Takahashi-Nishioka et al., 2008; Uludag, 2002; Zhang et al., 2007) . In order to overcome this, large doses must be taken with the consequent increase of the toxicity risk. As an example, most of the current anti-osteoporotic drugs are administered at higher doses to account for pharmacological interactions and expose the patients to adverse effects such as the endometritis, cancer risks and intrauterine haemorrhage on women who underwent prolonged oestrogen therapy (Rossouw et al., 2002) . Parathyroid hormone (PTH), a Food and Drug Administration (FDA) approved drug, is recommended to be administered only to severe cases for a maximum period of two years (Tashjian and Goltzman, 2008; Watanabe et al., 2012) . Bisphosphonates (BPs) oral therapy has been related with gastritis, gastric ulcer and erosive esophagitis (Graham, 2002; Naniwa et al., 2008) . Moreover, as anti-osteoporotic drugs may have to be taken for prolonged times, there is also a problem with patient therapy compliance. Other types of administration such as intravenous, nasal and transdermal delivery have also been addressed. Several drugs such as BPs, PTH and calcitonin can be administered intravenously to avoid first pass effects (Dodson, 2009; Schipper et al., 1994; Shi et al., 2015; Stirling et al., 1991; Tam et al., 1982; Tsavaris et al., 2006) but, because these drugs need to be given on a daily basis, this method of administration is inconvenient and difficult to follow through. Calcitonin is also available as a nasal spray, but the small surface area available and the rapid mucociliary clearance is very limiting (Dodson, 2009; Schipper et al., 1994; Stirling et al., 1991; Tam et al., 1982; Tsavaris et al., 2006) . Oestradiol can be delivered transdermally, by application to the skin, but not many drugs possess the physicochemical properties for this type of delivery (Shuid et al., 2013) . Currently, other than seeking new agents, efforts should be made in the development of innovative approaches that enable a specific and targeted delivery of therapeutics to bone and, therefore, improve drug efficiency and patients compliance while minimising adverse side-effects.
Despite having a fairly simple microscopic structure composed of 50-70 % mineral (primarily hydroxyapatite), 20-40 % organic matrix (mainly collagen type I), 5-10 % water and 1-5 % lipids, bone repair/regeneration entails significant challenges due to bone´s complex geometries and highly hierarchical and integrated structures, including hard and soft tissues (Ruppel et al., 2008) . Such structure, combined with the existence of a membrane of lining cells, which form a marrow-blood barrier and IS Alencastre et al.
Nanotechnology-based delivery systems to bone prevent the access of large exogenous substances to the bone surface (Travlos, 2006) , makes the development of bone-specific delivery systems a difficult task. Controlled drug delivery systems became available in the early 70s and are now a dynamic field of research (Jeong et al., 2002; Qiu and Park, 2001) . The most recent efforts are looking into the development of multifunctional and stimuli-sensitive nanoparticles with well-defined structures/patterns that allow the combined delivery of different therapeutic agents (such as anti-bacterial agents and osteogenesis and angiogenesis stimulators) in response to specific local stimuli (such as temperature, pH, ionic strength, ions, etc.), thus potentiating the therapeutic results (Caldorera- Moore and Peppas, 2009; Tautzenberger et al., 2012; Torchilin, 2014) .
To be considered a drug carrier, the material must be non-toxic (i.e. bioinert or biodegradable), biocompatible, able to incorporate a drug either physically or chemically, retain the drug up to the specific target without causing side effects in other cells or tissues, and have the capacity to deliver the drug in a controlled time manner (Bose and Tarafder, 2012) .
In the most recent strategies, different types of materials from biologics, polymers, silicon-based materials, carbon-based materials, metals, or combinations of them, structured in nanoscale formats are being considered (Satarkar and Zach Hilt, 2008) .
The choice of material depends on the therapeutics chemical characteristics (i.e, hydrophobicity or hydrophilicity, molecular size, isoelectric point, etc.), on the delivery rate intended, on whether materials degradation is desired or not, on the targeted bone, on the targeted cell(s) and on the size of the injury. Complementary, also the carrier´s structure, molecular weight, and drug release mode (such as by passive diffusion, carrier degradation, or degradation of a linker that connects the drug and carrier) have major effects on the efficacy of the drug delivery in a context-specific manner. Higher molecular weight carriers present longer circulating half-lives (that putatively potentiate the drug accumulation at the targeted diseased sites) but also an increased uptake by the reticuloendothelial system (RES) Wang et al., 2006) . Therefore, the carrier´s molecular weight, and ultimately its hydrodynamic radius, is a very important factor to take into account in drug delivery systems. Whenever the delivered therapeutics may be degraded by lysosomal enzymes, and does not create biocompatibility issues following RES uptake, high molecular weight and high targeting moieties may be advantageous over smaller ones. On the contrary, in cases where the drug´s metabolism by the RES is a concern, lower molecular weight carriers with lower percentages of targeting moieties can be recommended (Low and Kopecek, 2012) .
By presenting a similar size to bone ultrastructure, nanoparticles contain great potential as bone-specific carriers. The unique physicochemical properties of nanostructured biomaterials, such as being ultra-small and of controllable size, large surface area to mass ratio, presenting high reactivity and functionalisable structure has been widely explored by pharmaceuticals as means to circumvent some of the limitations of conventional drug delivery methods. In fact, when compared with traditional methods, drug delivery systems using nanoparticles present several advantages: i) circulation time is considerably increased due to the capacity to protect the drug from degradation and avoidance of its renal excretion; ii) drug bioavailability is improved and the solubilisation of lipophilic drugs is enhanced (due to the large surface area); iii) drug release can be performed in a controlled and sustained manner, with the consequent reduction on plasma level fluctuations and side-effects; and vi) drug delivery to specific sites, improving the protection of non-target tissues and cells (Moghimi et al., 2001; Papahadjopoulos et al., 1991; Torchilin, 2005) . Moreover, the surface modification of nanoparticles by polyethylene glycol (PEG) chains was shown to increase the circulation time (Klibanov et al., 1990) and is highly explored for the passive delivery of drugs such as the anticancer ones (Gabizon et al., 1994; Matsumura and Maeda, 1986) . Still, taking into consideration the above described features of higher molecular weight carriers, depending on the application, macromolecular and small molecule drug delivery should also be considered (Low and Kopecek, 2012) .
The drug loading in a carrier may be achieved by many means such as adsorption, incorporation, inclusion and connection through degradable linkers. The use of degradable linkers may be of upmost value for the tuning of the drug release profile. By inducing chemical modifications on the linker, either an immediate administration of high amounts of drug or small amounts of drug administered over an extended period of time may be obtained (Low and Kopecek, 2012) . Moreover, by including responsive linkers for bone targeting such as specific enzymes cleavage sites or pH-sensitive sequences, a precise site-specific release of the drug may be achieved (Mullen et al., 2014; Wang et al., 2013) . Several studies using sensitive linkers to metalloproteinases (expressed by osteoclasts, osteoblasts and overexpressed in many bone metastasis) Liu et al., 2015; Takaishi et al., 2008) , cathepsin K (expressed at resorption lacunae) ), cathepsin B (Ogbomo et al., 2013 , and acidsensitive linkers (such as hydrazone bonds) (Xu et al., 2015) have been shown to be effective for the drug release at specific cells/sites. In addition, characteristics such as elongated spacers Miller et al., 2008; Segal et al., 2009) and disulphide linkers (Kowalczyk et al., 2012; Kurtoglu et al., 2009 ) have also been considered for drug release into bone.
Presently, the number and complexity of the different therapeutics/biomaterials/technology combinations being investigated for targeted drug delivery in bone is very extensive. Although the effects of many of these systems have been widely approved in animal models, so far only very few have been approved for clinical use (Anderson et al., 2014) . Still, considering the large number of in vitro and in vivo preclinical studies currently ongoing this is now a very promising field of research.
Following, we provide an overview of the currently available approaches to drug delivery to bone. The pipeline advancements in computational and high-throughput approaches will be discussed. Cell-based therapies will not be encompassed.
IS Alencastre et al.
Nanotechnology-based delivery systems to bone Drug delivery systems to bone Systemic bone-related diseases (such as osteoporosis and osteoarthritis) may be better addressed with a systemic delivery system that releases the drug specifically to a broad range of bones in the body. Conversely, a localised injury (such as a critical fracture) may require a local delivery of the therapeutics that can be accomplished either by surgical implantation or by injection of the material at the targeted bone site (Fig. 1) .
Systemic drug delivery systems
Considering the very wide diversity of patients' conditions, bone targeting delivery systems for systemic administration would represent a less invasive route of application, being therefore ideal and more convenient. Drug carriers for systemic drug administration usually enable i) prolonged circulation time in plasma, ii) distribution and accumulation at the targeted tissue and iii) protection of the drug from enzymatic and chemical degradation.
Different physical parameters such as particle size (Alexis et al., 2008; Decuzzi et al., 2010; Petros and DeSimone, 2010) , shape (Decuzzi et al., 2010; Geng et al., 2007; Tao et al., 2011) , rigidity and softness (Merkel et al., 2011) have been shown to affect the particles' pharmacokinetics, targeting ability and cellular uptake. A significant number of researches have been focusing on active and passive targeting of systemically administrated particles to bone.
Oral administration
Successful oral delivery requires the protection of the drugloaded particles from degradation in the gastrointestinal tract and their safe transportation across the intestinal membrane. The mechanisms of micro-and nanocarriers oral uptake have been extensively investigated. Studies showed that nano-and microparticles are easily taken up by a group of localised endothelial cells in the small intestine, especially by Peyers patch (des Rieux et al., 2006; McClean et al., 1998) , with the consequent increase in the drug absorption. In addition, the incorporation of the drug into a particle core can protect it from the gastrointestinal IS Alencastre et al. Nanotechnology-based delivery systems to bone tract environment and thus increase the drug stability (Werle et al., 2006) and extend the blood circulation time of the drug (Leane et al., 2004) . Calcitonin and PTH are among the two most explored drugs in oral delivery systems for osteoporosis. Mucoadhesive devices (Gupta et al., 2013; Kawashima et al., 2000) and liposomal formulations (Garcia-Fuentes et al., 2005) , poly(L-lactide-co-glycolide) (PLGA) nanoparticles (Sang Yoo and Gwan Park, 2004 ) and pHsensitive microspheres (Lamprecht et al., 2004) have been tested in vitro and in vivo for the oral delivery of calcitonin, showing enhanced and sustained release of the drug. For the oral administration of PTH, PEGylated and thiolated chitosan nanoparticles loaded with PTH 1-34 showed increased drug half-life and improved bioavailability when compared to the bare peptide that is delivered systemically for treating osteoporosis (Narayanan et al., 2014; Takeuchi et al., 2003) . In a different study, PTH 1-34 encapsulated in an oral microemulsion delivery system (85:15, oil/water) consisting of Labrasol, Crodamol GTCC, Solutol ® HS 15, d-tocopheryl acetate (6:2:1:1, w/w) and saline water showed high drug loading efficiency (83 %) and permeability, and significantly higher resistance to proteolysis in vitro. The oral administration to osteoporotic rats showed increased bioavailability and improved bone microstructure .
Also in the treatment of autoimmune diseases such as rheumatoid arthritis, the use of biodegradable microparticles -first promoted for vaccine development -is now being addressed as an attractive option for an oral administration of auto antigens and inducing of oral tolerance (des Rieux et al., 2006) . Kim et al. (2002) showed that a single administration of PLGA nanoparticles entrapping type Π collagen could induce oral tolerance more efficiently than repeated oral administrations of intact type Π collagen. From the same lab, Lee et al. reported that the conjugation of PEG with immunodominant peptides for collagen-induced arthritis showed promising results as a delivery method for the induction of oral tolerance, rather than the whole Type II collagen and peptide (Lee et al., 2005) .
Delivery via the vascular system
Depending on the final objective, either the mineral portion of the bone (mainly composed of hydroxyapatite) or the bone marrow portion (constituted namely by progenitor cells and lipoproteins) can be targeted.
Targeting bone´s mineral fraction
Systemic delivery of therapeutics to bone can be achieved mainly by enhanced permeability and retention phenomenon, a result of the increased vascular pressure caused by the cytokines present in inflamed tissues or extravasation through vessels in or near the bone (Fang et al., 2011; Maeda, 2010; Maeda et al., 2009; Torchilin, 2011) . As bone´s vasculature is fenestrated with pore sizes up to 80 nm (Howlett et al., 1984) (exceeding the hydrodynamic size of most circulating nanomedicines), the targeting of hydroxyapatite by bone-seeking agents offers great possibilities.
Diverse compounds such as BPs, tetracyclines, acidic oligopeptides, and oestradiol analogues have been used to target bone diseases. These compounds have the capacity to bind hydroxyapatite differentially, depending on the crystal size and intrinsic molecule modifications. As the hydroxyapatite crystal structure or exposure is disease specific (for instance, hydroxyapatite crystals in a bone tumour are different from the crystals exposed in a bone fracture), precise targeting can be achieved by using targeting molecules with selectivity for different disease states (Low and Kopecek, 2012) . The binding rate of acidic oligopeptides to hydroxyapatite is faster than that of BPs but BPs have a superior binding strength and specificity for hydroxyapatite (Murphy et al., 2007) . BPs have the capacity to bind to all bone, while aspartate (Asp8, a common bone-targeting acidic oligopeptide) binds preferentially to higher crystalline hydroxyapatite, characteristic of resorption surfaces . Meanwhile, tetracycline deposits preferentially onto low crystallinity hydroxyapatite that is mainly present in growing surfaces . Altogether, when considering approaching bone mass indirectly by means of targeting the main cells responsible for bone formation (osteoblasts) and resorption (osteoclasts), osteoclasts are better targeted with acidic oligopeptides, and osteoblasts with tetracycline (Low and Kopecek, 2012) . BPs, such as alendronate (Alen), are distributed to both bone-formation and bone-resorption surfaces . More recently, (AspSerSer) 6 was found to be a targeting moiety in vivo for bone-formation surfaces (Zhang et al., 2012a) , constituting an alternative to tetracycline that presents several side effects such as teeth staining and inhibition of skeletal growth in children (Demers et al., 1968; Vennila et al., 2014) . Several preclinical studies considering different bone diseases have tested the potential of bone-seeking agents in conjugation with nanomedicines to be used as drug delivery systems to bone (Hirabayashi and Fujisaki, 2003) .
BPs are the most used bone-seeking agent in preclinical research. Different studies comprising BPs' conjugation to small molecules (Hirabayashi et al., 2001a; Hirabayashi et al., 2001b) , linear macromolecular carriers , proteins (Gittens et al., 2005) or nanoparticles (de Miguel et al., 2014; Park et al., 2003; Ross and Roeder, 2011) have been performed (Hirabayashi and Fujisaki, 2003) . BP-mediated bone targeting showed promising results in improving and prolonging the drug effects in different bone diseases approaches such as: prostaglandins (Gil et al., 1999 ), oestradiol (Bauss et al., 1996 Fujisaki et al., 1997; Fujisaki et al., 1998) , synthetic estrogenic agents (Tsushima et al., 2000) and nitric oxide (NO) (Lazzarato et al., 2005; Nichols et al., 2012; Zhang et al., 2007) in osteoporosis; nonsteroidal anti-inflammatory drugs (Hirabayashi et al., 2001b) in osteoarthritis; fluoroquinolones (Herczegh et al., 2002) in chronic infections treatment; and cisplastin (Klenner et al., 1990a) ; melphalan (Klenner et al., 1990b) , and methotrexate (Hosain et al., 1996; Yang et al., 2014) for the treatment of bone metastatic cancer. For further examples please see (Hirabayashi and Fujisaki, 2003) while (AspSerSer) 6 has been used in miRNA delivery for osteoporosis treatment (Ray, 2012; Zhang et al., 2012a) . Concerning gene therapy, an increasing number of molecular targets and nanotechnology-based strategies are being explored . The delivery of plasmid DNA using chitosan-based nanoparticles (Corsi et al., 2003; Lu et al., 2011; Zhang et al., 2006) and cationic polymers (Ohashi et al., 2001 ) has showed promising results for the treatment of joint diseases and osteosarcoma.
Alternatively, the popular RNA interference (RNAi)-based therapy using small interfering RNA (siRNA) is also exhibiting great potential both ex vivo and in vivo, to regulate progenitor cell differentiation pathways involved in osteogenic cell production for bone regeneration (Benoit and Boutin, 2012) . In this regard, considering the very low cellular penetration of siRNA (consequence of its large size and anionic nature) vectors that can provide a safe and efficient gene transfer are being extensively researched. Systemic targeted-delivery strategies usually resort to known bone-homing chemistry to bind mineralised phases of inorganic bone such as the FDA approved for clinical trials, dioleoyl trimethylammonium propane-based liposomes conjugated with the targeting oligopeptide peptide (AspSerSer) 6 (Zhang et al., 2012a) . In bone repair, several gene silencing such as Noggin (Manaka et al., 2011) , receptor activator of nuclear factor κ B (RANK) , NFκβ (Yao et al., 2009) ; Src (Zheng et al., 2015) ; osteopontin and osteocalcin (Zhang et al., 2010) , have been explored as a mean to regulate bone formation and mineralisation. As an example, polylactide (PLA)-polydioxanone-PEG copolymer hydrogels loaded with Noggin siRNA and bone morphogenetic protein (BMP-2) implanted into mouse dorsal pouches resulted in the stimulation of ectopic bone formation, with higher bone mineral content and greater bone quantity than that observed by delivery of an equivalent dose of BMP-2 alone (Manaka et al., 2011) . Layer by layer film composed of alternating layers of calcium phosphateshRNA nanoparticles and PLL presented a sustained silencing effect for 21 d in human osteoblasts grown on the films (Zhang et al., 2010) . For Ewing's sarcoma (EWS), diamond nanoparticles coated with cationic polymer (nanodiamonds, NDs) have successfully been used to deliver siRNA into EWS cells where they achieved specific inhibition of EWS/Fli-1 gene expression at the mRNA and protein levels showing therefore promising data for tumour treatment (Alhaddad et al., 2011; Toub et al., 2006) . In a different study, a polymer carrier for the delivery of siRNA to silence two distinct pathways, the PLK1 pathway for osteosarcoma cancer cells and the ERK1/2 pathway in osteoarthritis, as has been shown to slow down the progress of the diseases (Truong et al., 2013) .
In cell therapeutics, nanotechnology has been mainly explored for cell labelling procedures. Quantum dots, superparamagnetic and gold nanoparticles-cell labelling during regenerative therapies has been efficiently used for the visualisation and tracking of the cell transport to the area of the defect in vivo, and for the assessment of the fate and participation of the transplanted cells in tissue regeneration. Pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs) and adipocyte-derived stem/stromal progenitor cells (ASCs), are currently under extensive investigation using tissue engineering strategies for bone regeneration applications (Tautzenberger et al., 2012; Vo et al., 2012) , namely in combination with siRNA delivery, but such approaches will not be encompassed in this review.
Targeting bone marrow cells
Together with its functions in haematopoiesis and in the immune system, bone marrow cells have also been implicated in many bone disorders such as rheumatoid arthritis, bone regeneration and repair, bone metastases and osteoporosis (Delaisse, 2014) , constituting therefore a relevant target for potential therapies ( Table 2) .
The traditional drug delivery to bone marrow relied on uncontrolled passive diffusion through blood circulation. This is a highly ineffective method, with only a very small fraction of drugs reaching the target site. Therefore, the development of bone marrow-targeted drug delivery carriers offers great potential to the development of more efficient diagnostic and therapeutic systems. Both in vitro and in vivo tests using liposomes, polymers, microspheres, nanoparticles, silicon particles, and polypeptides as drug carriers have showed efficient targeting of bone marrow cells (Harris et al., 2010; Luhmann et al., 2012; Mann et al., 2011; Porter et al., 1992; Schettini et al., 2006; Sou et al., 2010; Sou et al., 2011) . In a study by Chi et al. (2010) dendritic amine and guanidinium group-modified nanoparticles were investigated for the delivery of model peptide drug into primary osteoclast precursor cells showing a significant cellular uptake of the nanoparticles (Chi et al., 2010) . (Porter et al., 1992) showed that polystyrene particles coated with the block copolymer poloxamer-407, a non-ionic surfactant, would selectively redirect intravenously injected microspheres to sinusoidal endothelial-cells of rabbit bone-marrow (Porter et al., 1992) . Particles of 150 nm in diameter and below evaded recognition by Kupffer cells and efficiently accumulated in sinusoidal endothelial cells of rabbit bone marrow (Porter et al., 1992) . Importantly, no marked uptake was achievable with other block co-polymers having a similar structure to that of poloxamer-407, suggesting the participation of a specific interaction mechanism between the particle and the sinusoidal endothelial cell surface. After several years, the concept of active targeting to bone marrow endothelial cells was recently recharged. In a study by Chi and co-workers, dendritic amine and guanidinium group-modified nanoparticles were investigated for the delivery of model peptide drug into primary osteoclast precursor cells showing a significant cellular uptake of the nanoparticles (Chi et al., 2010) . Harris et al. prepared cationic nanoparticles with plasmid DNA and then coated their cationic surface with poly(anionic)poly(glutamic acid)-based peptides, with and without cationic insert, and showed that the terminal sequence insert, cationic amino acid sequence G-dP-dL-G-dV-dR-G, to the poly(glutamic acid)-based peptides is a critical factor for enhancing bone marrow and spleen-specificity of gene delivery in vivo (Harris et al., 2010) .
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Based on the evidence that E-selectin, expressed on normal endothelial cells in response to inflammatory stimuli, is constitutively expressed in bone marrow endothelium and is involved in leukemic cell homing (Sipkins et al., 2005) , Mann and co-workers developed porous silicon particles modified with E-selectin thioaptamer ligands to target bone marrow endothelium (Mann et al., 2011) . Studies on mice demonstrated an 8-fold increase on the accumulation of porous silicon particles modified with E-selectin compared to control porous silicon particles, which were accumulated primarily in the liver and spleen instead of bone marrow (Mann et al., 2011) .
The microvascular bed in cortical bone consists of endothelial cells with no phago-endocytotic activity nor fenestration, and restricts the passive transvascular transport of macromolecules to particles that are able to pass ~ 5 nm pores within the endothelium. In contrast, sinusoidal blood capillaries in bone marrow are characterised by diaphragmed fenestrae and phagoendocytotic activity of endothelial cells (Sarin, 2010) . Systemically administered particles may permeate sinusoidal endothelium and be sequestered into bone marrow, which has been explored for bone marrow imaging using radiolabelled albumin microspheres and microaggregates (10-30 nm) and polyvinylpyrrolidone nanoparticles (1-13 nm) (Moghimi et al., 1990) . Liposomes consisting of distearoylphosphatidylcholine (DSPC), cholesterol, PEG(5000)-DSPE, and α-tocopherol prepared in various sizes (136-318 nm diameter) have been tested for organ distribution in rabbits but none of these liposomes showed a significant accumulation in bone marrow (Awasthi et al., 2003) .
Overall, active and passive targeting of systemically administered particles to the bone marrow remains a challenging task. Presently, the active targeting of particles through the sinusoidal epithelia of bone marrow is a promising approach to targeted deposition of delivery systems in the bone marrow. Most studies suggested a predominant role of specific targeting over particle size for accumulation in bone marrow, but systematic studies are still required.
Local drug delivery systems
Although implicating a more invasive approach, the local delivery of drugs, entails some advantages over the systemic delivery: i) the drug quantity necessary is reduced, ii) unwanted side effects on other cells or organs/ tissues is minimised, iii) drugs are retained and kept in the local for increased periods, increasing the treatment time and efficacy and iv) the adequate tuning of the delivery system allows a time-controlled delivery according to the requirements.
Ideally, local drug delivery system to bone should be designed to deliver the drug through minimally invasive procedures, such as by injection to the local site, and possess the ability for in situ matrix formation. In this way, wound healing would be significantly accelerated, requirements of irregular shape defects are more easily met and patients comfort and compliance is increased (Xu et al., 2008; Yasmeen et al., 2014) . Moreover, materials should be biodegradable, able to uptake large quantities of drug, retain the drug at the desired site and release the drug slowly to the bone and surrounding tissue.
Delivery systems for the local drug release are the most investigated approach in bone therapeutics and the design options are virtually unlimited. Still, for clinical applications novel injectable biomaterials with improved properties such as mechanical strength, biocompatibility, and vascularisation are necessary.
The most investigated drugs in local drug delivery systems to bone are anti-cancer drugs, BPs and growth factors. Numerous organic, inorganic and combined systems are available for the local drug delivery into bone. Organic nanoparticles include lipids, dendrimers, chitosan, carbon nanotubes (Moore et al., 2013) , nanoparticles such as poly-L-lysine (PLL), PLA, polyglycolic acid, polycaprolactone (PCL) or copolymers of these such as PLGA. The inorganic nanoparticles are usually composed of silica, hydroxyapatite, or metals such as gold, silver and iron (Tautzenberger et al., 2012) . In Table 3 we present exemplary studies on different materials used in local delivery of therapeutics to bone.
Depending on their interaction with the host tissue, materials can be divided in bioinert and bioactive. It is now clear that besides the composite, the inherent nanostructure, namely the hierarchical porous structure, plays a major role the bioactivity level of bioactive materials. For this reason, in the past decade, synthesis and application of mesoporous solids, with highly ordered structures, high surface area and large pore volume have been significantly investigated for the encapsulation of pharmaceutical therapeutics . This material has showed excellent performance in both controlled drug delivery with sustained release profiles and formulation of poorly aqueous soluble drugs with enhanced bioavailability (Shen et al., 2013) . With the preparation of the first mesoporous bioactive glasses (MBG) in 2004 by Yan et al., (Yan et al., 2006; Yan et al., 2004) , the combination of drug delivery with bioactive materials was achieved, starting a new model for improved bone regeneration applications by the functional effect of nanomaterials. These materials are based on a CaO-SiO 2 -P 2 O 5 composition and have a highly ordered mesopore channel structure with a pore size ranging from 5-20 nm. Compared to conventional non-MBGs, the MBGs have improved surface area, pore volume, ability to induce in vitro apatite mineralisation in simulated body fluids, and excellent cytocompatibility (Alcaide et al., 2010; Li et al., 2007a; Yan et al., 2006) . Moreover, MBG 3D porous scaffolds can be prepared by high-throughput techniques and can, therefore, yield a highly controlled material structure to be used in bone tissue engineering and drug delivery applications (Wu and Chang, 2012) . Different studies have reported an efficient therapeutics delivery to bone by means of MBG scaffolds (Wu and Chang, 2012; Wu et al., 2013; .
Functional ions, such as Li, Sr, Co and B; small molecular drugs like dexamethasone, dimethyloxaloylglycine (DMOG), and gentamicin; and growth factors such as vascular endothelial growth factor (VEGF) and BMP loaded into MBG scaffolds showed great potential as a release IS Alencastre et al.
Nanotechnology-based delivery systems to bone system to enhance osteogenesis, angiogenesis and antibacterial/cancer activity . Li, Sr, Mg, Cu, Fe, B and Zr presented a positive effect on osteogenesis. Cu and Co ions were shown to stimulate angiogenesis and Ag and Cu ions showed anti-bacterial activity. The combined release of Si ions with Li, Sr, Cu displayed a synergistic effect and a further enhancement of the osteogenesis and angiogenesis. The delivery of therapeutic drugs and growth factors, such as Dexamethasone, DMOG, BMP and basic fibroblast growth factor (bFGF) from MBG, significantly promoted in vitro and in vivo osteogenesis. DMOG and VEGF release showed an increase of angiogenesis. Gentamicin and ampicillin delivery inhibited the bacterial activity and doxorubicin presented anti-cancer effect .
Although nanoparticles alone can provide sustained and even sequential release in vitro (Chen et al., 2011a; Yilgor et al., 2010) in bone tissue engineering applications, their incorporation into a scaffold or hydrogel matrix creates additional control over the kinetic properties, increasing treatment efficacy and specificity for improved bone repair (Isikli et al., 2012; Nandagiri et al., 2011) . Most frequently, nanoparticles are combined with scaffolds such as solid implants, hydrogels or degradable polymeric matrixes, which can be stimulus responsive or have preprogrammed release kinetics to deliver bioactive molecules in a localised, spatiotemporal manner in agreement with the natural wound healing process. Complementary to this, the scaffold should provide support for cell migration, proliferation, synthesis extracellular matrix Table 3 . Exemplary studies on different materials used in local delivery of therapeutics to bone.
Abbreviations are listed in Table 1 .
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and establishment of vascular networks. Properties such as injectability and in situ forming gels have also been highly explored in order to minimise surgical procedures (Yasmeen et al., 2014) . Again, a large variety of inorganic, natural, and synthetic materials have been used for the generation of controlled system scaffolds (Vo et al., 2012) .
Hydrogels
Hydrogels are among the most studied materials for the development of novel delivery systems for bone regeneration by combining a good biocompatibility with the capacity to provide the controlled release of functional therapeutics and a tissue-compatible substrate for cell attachment and growth, simulating an artificial extracellular matrix (Vo et al., 2012) . They are a class of hydrophilic, crosslinked polymeric networks, insoluble in water that possess the ability to hold large amounts of fluids within its structure: Very different experimental settings ranging from different materials sources to the cross-linking degree, the drug-loading and release mode are being, explored with the purpose of drug delivery to bone. The most explored therapies concern protein, antibiotics and cell delivery. Both synthetic materials, such as PEG-based polymers (Lin and Anseth, 2009; Milleret et al., 2014) , and natural polymers like gelatine (Young et al., 2005) , alginate (Kolambkar et al., 2011; Miao et al., 2014; Rubert et al., 2013) , fibrin (Hong et al., 2014; Yang et al., 2010) , and hyaluronic acid (Kim et al., 2007) are being considered. Studies in a rabbit segmental defect and mouse subcutaneous implantation model propose an optimum hydrogel water content and crosslinking density for synchronised delivery and bone formation (Kimura et al., 2010; Yamamoto et al., 2006) . Moreover, "stimuli-responsive" or "smart" hydrogels, with the capacity to respond to external stimuli, such as pH, temperature or electric stimuli are being developed (Basak et al., 2014; Sood et al., 2014) creating exciting new opportunities for controlled drug delivery.
Still, among their characteristics, hydrogels also possess weak mechanical properties and low bioactivity (Shaikh et al., 2010) and the most recent strategies in this field are focusing in the combination of hydrogels with nanofillers, such as carbon nanotubes in a way to surpass such setbacks (Cirillo et al., 2014; Yasmeen et al., 2014) . The development of injectable, stimuli-responsive gels containing hydroxyapatite and carbon nanotubes as nanofillers are among the latest approach in hydrogels delivery systems to bone (Yasmeen et al., 2014) .
Stimulus responsive
In recent years, biomaterials research as advanced from the investigation of biocompatible and biodegradable materials to the design of stimuli-responsive biomaterials that can respond to a variety of stimuli, including selective physical (e.g., temperature), chemical (e.g., pH and ionic strength) and biomolecular recognition (e.g., enzyme, peptide-and lipid-based interactions) stimuli . Some of these stimuli, like the pH in different cellular compartments or disease states, occur naturally in vivo, while others, such as light and ultrasounds, are externally controlled allowing the external temporal and spatial control of the release (Fleige et al., 2012) .
Considering the fact that bone repair entails a combination of sequential and cooperative signalling events in response to changes in their microenvironment the incorporation of stimulus-responsive elements into therapeutics delivery vehicles allows for improved biomimetic strategies.
Temperature and pH-sensitive polymers are among the most studied stimulus-responsive materials, mainly in combination, to form dual-responsive delivery systems. Temperature-sensitive polymers generally show low critical solution temperature behaviour, where if a certain temperature threshold is surpassed the polymer undergoes a reversible phase transition that can be exploited for drug release. By varying the hydrophilic or hydrophobic co-monomer content the low critical solution temperature can be tuned to create the desired temperature transition (Shaikh et al., 2010) . pH responsive polymers result from the presence of weakly acidic (e.g., carboxylic and sulphonic acids) and/or weakly basic (e.g., ammonium salts) functional groups on the polymeric backbone, which allow for reversible swelling/de-swelling behaviour in acidic or basic media (Shaikh et al., 2010) . Poly(Nisopropylacrylamide) (Garbern et al., 2010; Na et al., 2007) , poly(organophosphazenes) (Chun et al., 2009) , PEG-based di/tri block copolymers (He et al., 2008) , PCL (Kim et al., 2006) and their derivatives as well as biomimetic materials like chitosan, dextran and elastin-like peptides (Bessa et al., 2010; Patois et al., 2009) are the most usually temperature-responsive polymers used: Among the pHsensitive carriers, the Poly (vinyl alcohol) and poly(acrylic acid) are amid the most common examples (Kurkuri and Aminabhavi, 2004; Zhang et al., 2012b) . Moreover, also pH-sensitive linkages such as hydrazone, hydrazide and acetal are extensively used for drug conjugation to a polymeric backbone (Fleige et al., 2012) . As an example, for bone tissue engineering, in vivo analysis of a pH/ thermo-sensitive sulphamethazine oligomers (SMO)-poly (ε-caprolactone-co-lactide) (PCLA)-PEG-PCLA-SMO block copolymer loaded with human mesenchymal stem cells (hMSCs) and BMP-2 (Kim et al., 2009) showed hMSC differentiation for up to 7 weeks, mineralised tissue formation and high levels of alkaline phosphatase activity. For osteomyelitis treatment (Peng et al., 2010a; Peng et al., 2010b ) developed a thermosensitive implant composed of PEG monomethyl ether (mPEG) and PLGA copolymer (mPEG-PLGA) for teicoplanin delivery. Histological staining and immunoblotting analyses in rabbits showed that the mPEG-PLGA hydrogel containing the antibiotic teicoplanin was effective in treating osteomyelitis (Peng et al., 2010b) . In osteoarthritis, the delivery of the antiinflammatory celecoxib by a fully acetyl-capped PCLA-PEG-PCLA triblock copolymer hydrogel showed to be a safe drug delivery platform for sustained intra-articular release (Petit et al., 2014) .
In a different approach, the biochemically triggered drug release can be attained by incorporation of cleavable peptides for enzymatic degradation such as matrix metalloproteinase peptide crosslinkers (Chung et al., 2006;  IS Alencastre et al.
Nanotechnology-based delivery systems to bone Fonseca et al., 2014; Lutolf et al., 2003) . Enzyme-cleavable peptides can also be used to connect proteins and pro-drugs for delayed release and activation in response to cell infiltration (Arrighi et al., 2009; Purcell et al., 2014; Wilson and Guiseppi-Elie, 2013) . Additional drug release approaches in response to magnetic, ultrasound, irradiation and electric stimuli have also been explored (Torchilin, 2014) . Magnetic nanoparticles are in fact a popular approach for local bone delivery allowing a controlled, spatio-temporal release of different drugs by the use of a magnetic field after implantation in vivo (Akbarzadeh et al., 2012; Li et al., 2016) . Moreover, this also permits the creation of drug gradients and long term sustained release (Sensenig et al., 2012) . In a study by Butoescu et al., dexamethasonecontaining superparamagnetic iron oxide nanoparticles (SPIONs) co-encapsulated into PLGA microparticles showed excellent biocompatibility with synoviocytes, and suggested that this type of carrier could be used as a suitable magnetically retainable intra-articular drug delivery system for treating joint diseases such as arthritis or osteoarthritis (Butoescu et al., 2009) . For bone tissue engineering, in vitro analysis of clodronate loaded hydroxyapatitemagnetite-multi-walled carbon nanotubes nanocomposite showed good results as a multimodal platform combining the effect of bone biomineralisation induced by HApbased composites with the decrease of osteoclast formation induced by the drug (Pistone et al., 2014) . In a different study, three-dimensional (3D) magnetic Fe 3 O 4 nanoparticles containing mesoporous bioactive glass/ PCL (Fe 3 O 4 /MBG/PCL) composite scaffolds loaded with doxorubicin as a model anticancer drug exhibited potential multifunctionality of enhanced osteogenic activity, local sustained drug release and magnetic hyperthermia in vitro (Jianhua Zhang, 2014) .
Combined delivery
Bone healing involves the intervention of a complex and well spatio-temporal-orchestrated set of factors (Dimitriou et al., 2005; Tsiridis et al., 2007) . In this regard, the incapacity to mimic the complex tissue architecture and to provide the necessary biochemical and cellular microenvironment is a major challenge in tissue regeneration.
Studies have shown that sequential and spatiotemporal drug release may lead to improved tissue regeneration by providing physiologically relevant release profiles and spatial gradients that mimic the natural healing response Santo et al., 2013; Vo et al., 2012) . The designing of multi-functional nanomaterials that enable the simultaneous, sequential and spatially-controlled delivery strategies of different therapeutics have been developed to recapitulate the early expression of factors for bone regeneration.
Several in vitro and in vivo studies have investigated the synergistic effects of dual growth factor delivery (BMP-2, BMP-7, VEGF, transforming growth factor (TGF)-β-3, Insulin-like growth factor 1 (IGF-1)) using different scaffold composites such as alginate, periodontal ligament fibroblasts, PLGA, gelatine and nanodiamonds, for numerous bone and cartilage regeneration applications (Basmanav et al., 2008; Chen et al., 2009; Facca et al., 2010; Kanczler et al., 2010; Moore et al., 2013; Patel et al., 2008; Richardson et al., 2001; Simmons et al., 2004) showing improved results in comparison with the single delivery. In a recent study, the simultaneous delivery of BMP-2 and bFGF by nanodiamonds has showed good results for the promotion of bone cell differentiation and proliferation in vitro (Moore et al., 2013) .
Combined delivery of growth factors and drugs has also been addressed as shown in a study of Choi et al. , where a dual and time-controlled release of BMP-2 and dexamethasone from PLGA-core/alginate-shell microcapsules fabricated with coaxial electro-dropping was investigated (Choi et al., 2010) . In the past 5 years, MBGs have also been largely investigated for the combined delivery of therapeutic ions and drug/growth factors . Still, all in vivo reports of enhanced bone formation upon combined delivery of growth factors have been performed in ectopic, but not orthotopic models and further studies are necessary.
In a different approach, the time-dependence requirements of delivery have been investigated. Gelatine microparticles-loaded poly (propylene fumarate) scaffolds showed that bone formation in a rat calvarial critical size defect was BMP-2 dose-dependent and that VEGF combined delivery was beneficial on bone regeneration at 4 weeks, but not at 12 weeks (Patel et al., 2008; Young et al., 2009) . Also, the sequential release of VEGF and BMP-2 from PLGA microsphere-loaded poly(propylene fumarate) scaffold-gelatine hydrogel composites in a rat femoral defect over 8 weeks showed suboptimal bone formation (Kempen et al., 2009) .
In order to mimic the physiological concentration gradients that provide the topological signals for tissue formation, the impact of spatial delivery has also been addressed. Silk fibroin microspheres immobilised in a 3D porous silk scaffold where used for the simultaneous release of linear gradients of recombinant human BMP-2 and IGF-1 -showing enhanced osteogenic and chondrogenic differentiation of hMSCs over 5 weeks along the gradients .
Multilayered scaffolds constitute a unique platform that enables multiple delivery of therapeutics through incorporation of different phases into scaffolds for differential release kinetics and spatially controlled drug release. Bi-layered oligo(poly(ethylene glycol) fumarate) and gelatine microparticles hydrogels developed by (Guo et al., 2009; Guo et al., 2010) showed enhanced chondrogenic differentiation of encapsulated rabbit MSCs in vitro with delivery of TGF-β1 or TGF-β3 in the chondrogenic layer and co-culture with pre-differentiated osteogenic cells in the lower bone-forming layer (Guo et al., 2010; Guo et al., 2009) . More recently, the potential of layer-by-layer technique has been successfully applied for the development of multilayered coating scaffolds for controlled drug delivery for orthopaedic implant applications (Kunjukunju et al., 2013; Min et al., 2014) .
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High-throughput processing techniques
Manufacturing techniques like electrospinning, bioprinting, and layered scaffolds/membranes (Fig. 2) , are among the latest techniques being pursued to produce tissue constructs and engineered scaffolds with pre-designed macro-microand nano-features, gradient physic-chemical properties and custom shapes for tissue engineering therapies.
Electrospinning is a technique that produces fibrous scaffolds and films through electrostatic repulsion of liquid polymer solutions using a high-voltage source creating nano/micron-sized fibres suitable for cell attachment and growth. Their orientation and geometries for therapeutics release can be controlled by collecting the extruded fibres on various static or rotating plates. Several studies reported sustained release of therapeutics to bone from electrospun scaffolds (Dong et al., 2014; Mi et al., 2014; Ramier et al., 2014; Ren et al., 2014; Sahoo et al., 2010; Srouji et al., 2011; Tetteh et al., 2014) . As an example, in a study by Sahoo et al., PLGA nanofibers incorporated with bFGF, fabricated using the facile technique of blending and electrospinning (Group I) and by the more complex technique of coaxial electrospinning (Group II) presented prolonged growth factor release that positively influenced stem cell behaviour and fate (Sahoo et al., 2010) .
Moreover, exciting new technology such as biopatterning offers a more precise and efficient control of drug delivery than conventional techniques. Biopatterning is a promising approach in bone tissue engineering, used to immobilise growth factors and cells onto 3D scaffolds with persistent patterns that subsequently control cell migration, proliferation and differentiation. In this technique a precise positioning of biological materials, biochemicals and living cells, with spatial control of the placement of functional components, is used to fabricate 3D structures (Guillemot et al., 2010) . Cooper et al. used acellular-derma-matrix constructs patterned with BMP-2 and signalling noggin protein implanted into a mouse calvarial defect model showing that three-dimensional biopatterning of a growth factor and growth factor modifier within a construct can direct cell differentiation in vitro and tissue formation in vivo according to printed patterns (Cooper et al., 2010) . In a similar study, Herberg et al. showed that sustained release delivery of a low-dose growth factor therapy (BMP-2, stromal cell-derived factor-1β and TGF-β1), and co-therapies using inkjet-based biopatterning of acellularderma-matrix can aid healing in mouse calvarial critical size defect (Herberg et al., 2014) . Gao et al. evaluate bioactive ceramic nanoparticles (glass (BG) and hydroxyapatite) in stimulating osteogenesis of printed bone marrow-derived hMSCs in poly(ethylene glycol) dimethacrylate scaffold. Results highlighted the technology capacity cell delivery into hard tissue engineering with biomimetic structures (Gao et al., 2014) . This strategy enables the design of spatially customised anatomical architecture in a patientand defect-specific manner.
Layer-by-layer assembly of nanoparticles and coatings allows for the modification of the material´s surface properties, enabling a controlled release of desirable substances (Min et al., 2014) . By using this technique, stronger bonding of implants to bones can be achieved as well as the controlled release of antibiotics or antimicrobial agents to prevent infection (Gaudiere et al., 2014; Shah et al., 2013; Yang et al., 2009) .
A list of currently ongoing approaches for the biomaterial-based delivery of therapeutics for different bone diseases is listed in Table 4 .
In silico mathematical models for the skeletal system Mathematical modelling has been shown to be an important tool in the optimisation of drug delivery systems (Siepmann and Siepmann, 2008) . Advanced modelling and in silico experiments can be useful in different components of the optimisation process, such as calculation of optimal drug release profiles (Raiche and Puleo, 2001 ) specification of structure and dimensions of delivery systems (Velghe et al., 2014) , or to speed up product development (Siepmann and Siepmann, 2012) , just to name a few.
Mathematical and computational models provide detailed quantitative descriptions of a system by capturing, in one or more mathematical expressions, its main dynamics and properties. Models are, of course, an abstraction of the real systems, with underlying simplifications and assumptions, but have the potential to isolate and quantitatively describe the mechanisms of Table 4a . Biomaterial-based delivery of therapeutics for bone diseases.
Abbreviations are listed in Table 1. interest and its causal dependencies. Two key concepts underlie the use of mathematical models in the optimisation of drug delivery systems, as in other research fields: 1) hypothesis testing -assess if a conceptual model is in fact a proper description of the mechanism(s) of interest in the real system; and 2) prediction -given partial information about the state and parameters of the system, be able to infer unknown variables (usually prediction is used in the context of producing estimates for variables of interest at future time instants). Both situations have been used in the quest to better understand and optimise the drug delivery systems (Peppas, 2013; Siepmann and Peppas, 2001a; Siepmann and Siepmann, 2008) . In order to capture and predict the spatiotemporal properties of drug delivery, existing mathematical models focus on the following mechanisms associated with the delivery system: diffusion, swelling, erosion and drug binding affinity (Arifin et al., 2006; Lauzon et al., 2012; Siepmann and Siepmann, 2008) . While for presentation purposes the following section addresses each one of these mechanisms separately, in practise most models blend together these theories in order to produce more realistic descriptions of the drug delivery systems. This means that different types of scaffolds developed for drug delivery typically require more than one of the above mentioned core mechanisms to be properly modelled. Mathematical models, independently of the mechanism they try to describe, can either be empirical or mechanistic depending on the level of simplification used: mechanistic models include an explicit representation of mass transport mechanisms and biochemical reactions (Korsmeyer et al., 1986a) ; empirical models try to directly capture the Table 4b . Biomaterial-based delivery of therapeutics for bone diseases.
Abbreviations are listed in Table 1. IS Alencastre et al. Nanotechnology-based delivery systems to bone drug release profiles without explicitly stating the internal generating mechanisms (Higuchi, 1961; Peppas, 1985) . While mathematical and computational models of drug delivery is a field in rapid development, very few studies exist in the context of the skeletal system (Lauzon et al., 2012; Lauzon et al., 2014; Makarov et al., 2014; Raiche and Puleo, 2001 ).
Models for diffusion controlled systems
Mechanistic models for diffusion controlled systems are grounded in the principle of mass conservation. This principle states that in a closed system, total mass is conserved: it can neither be created nor destroyed, but it can be rearranged in space (through the action of fluxes). Given its dependence in both space and time, mechanistic models for diffusion controlled systems need to be described by partial differential equations, relating the drug concentration (C), with transport mechanisms (flux, F) and the existing drug sources and sinks (f):
1
The symbol represents the mathematical operator divergence. The physical significance of the divergence of the flux F can be seen as the rate at which drug density exits a given region of space (Fig 3) . Each of the variables C, F and f may be functions of both time and space.
In the absence of transport mechanisms other than diffusion, the flux is given by Fick's first law: 2 where D is the diffusion coefficient (which may also be a function of time and space). Initial conditions, geometry and boundary conditions all play a crucial role in the solutions of the mass conservation equation. One of the most frequently used approaches is to discard interactions of the active molecules with the environment and consider only the pseudo steady-state (Higuchi, 1961; Siepmann and Peppas, 2011) . Other models have, however, considered less simplified conditions (Makarov et al., 2014; Siepmann and Siepmann, 2012; Tzafriri et al., 2005) including different geometries (Grassi and Grassi, 2005; Helbling et al., 2011; Raiche and Puleo, 2001 ), moving boundaries (Manitz et al., 1998) , hydrogel network design (Lin and Metters, 2006) , drug dissolution (Siepmann and Siepmann, 2013) , and vesicle design (Mosley et al., 2013) .
Models for swelling controlled systems
Some polymer matrix delivery systems are subject to polymer swelling with important consequences in the properties and dynamics of drug release. This swelling affects transit times and diffusion properties by increasing the volume and changing the properties of the medium where the flux is taking place. Altering the diffusion pathways, and subsequently the concentration gradients, can produce significant changes in the drug release properties (Siepmann and Siepmann, 2008) . Models dealing with swelling are therefore more complex than simple diffusion models, as they have to account for changing geometries and/or boundary conditions as well as inhomogeneous diffusion coefficients (Korsmeyer et al., 1986a; Korsmeyer et al., 1986b; Siepmann and Peppas, 2001b) .
Models for erosion controlled systems
Polymer erosion and degradation are other properties that can be carefully engineered to enhance tissue treatment. In the case of bone repair, generally the scaffolds must be resorbed to provide efficient healing (Lauzon et al., 2012) . The process of erosion/degradation can be modelled as a combination of stochastic hydrolysis and mass transport (Chen et al., 2011b) , autocatalytic hydrolysis (Ford Versypt et al., 2013) , diffusion and chemical reactions (Siepmann and Gopferich, 2001 ). An extensive review of different mathematical models addressing polymer erosion of the context of drug delivery is presented in (Sackett and Narasimhan, 2011).
Models for affinity controlled systems
In some delivery systems the interactions between drug and scaffold need to be accounted for in order to produce a plausible and realistic model of the drug release. In these models the mass conservation equation together with Fick's first law are used in combination with biochemical (kinetics) equations describing the affinity interactions (Fu et al., 2011; Lauzon et al., 2012; Lauzon et al., 2014) . Fig. 3 . Principle of mass conservation in a system with spherical symmetry. The nanoparticles/drug concentration, as a function of time and distance to the delivery system core, is described by the present fluxes J (e.g., diffusive) and the delivery and degradation dynamics, captured in the component f.
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Conclusions and future perspectives
The relevance of nanobiotechnology in the improvement of drug delivery systems is now unquestionable and assumes a central role in the progression of human therapeutics. Recent research has clearly demonstrated the potential of nanotechnology in the development of drug delivery systems to a vast range of bone disorders. Present pharmaceutical efforts are shifting from the search for new drugs into the investigation of novel approaches that enable a specific and targeted delivery of therapeutics to bone that may improve drug efficiency and patient compliance, while minimising adverse side-effects. Targeted delivery systems based on bone seeking agents resulted in enhanced distribution of therapeutic agents to bone tissue. Local administration based on nanoparticles and hydrogels that slowly released incorporated drugs presented a sustained therapeutic effect in disease site and most recently, smart drug delivery systems that respond to various stimuli have been investigated to attain the controlled and site-specific delivery of drugs. Complementary, diverse high throughput technologies and in silico approaches are currently facing a steep development and improvement. By enabling the precise processing of materials and the establishment of very fine mathematical formulation, comprising highly tuneable/case-specific parameters, such technologies represent a very exciting step forward for the achievement of the desired personalised drug delivery approach.
Although offering great potential, significant challenges and limitations in this field must be addressed in order to make drug delivery systems to bone an effective clinical reality. One of the major handicaps is the lack of knowledge of the pathological and biochemical pathways involved in specific disease states. A deeper understanding of the disease-specific underlying mechanisms and time frames would allow the design of more accurate tailored systems with enhanced effectiveness and the development of precise synergistic drug delivery systems to bone. Nanobiotechnology-based drug delivery strategies to bone have a very wide range of applications and represent an exciting and very promising field of research with the potential to significantly improve the quality of life for millions of people. 
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